Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEDI 3617 (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune

Most Recent Events

  • 20 Mar 2018 Results (n=116) assessinf tolerability and pharmacokinetics of MEDI 3617 in subjects with advanced solid tumours, refractory to standard therapy as monotherapy and in combination with bevacizumab, carboplatin and paclitaxel, were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
  • 03 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 14 Aug 2015 Planned End Date changed from 1 Jun 2017 to 1 Nov 2015 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top